SE
61
-4
A
43
2
AN
58
4
MCHP
41
4
WEC
53
-2
CRM
67
2
DFS
64
2
ORLY
62
2
MCD
52
2
VZ
50
3
CA
38
6
KEY
46
3
GOOGL
40
-5
DE
63
3
CFG
70
6
MPC
44
-3
BK
74
2
EOG
58
2
RSG
71
3
EBAY
47
4
SE
61
-4
A
43
2
AN
58
4
MCHP
41
4
WEC
53
-2
CRM
67
2
DFS
64
2
ORLY
62
2
MCD
52
2
VZ
50
3
CA
38
6
KEY
46
3
GOOGL
40
-5
DE
63
3
CFG
70
6
MPC
44
-3
BK
74
2
EOG
58
2
RSG
71
3
EBAY
47
4
Financhill
Back

BridgeBio Pharma 10K Form

Buy
57

BBIO
BridgeBio Pharma

Last Price:
23.44
Seasonality Move:
10.74%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BBIO News And Ratings

See the #1 stock for the next 7 days that we like better than BBIO

BBIO Financial Statistics

Sales & Book Value

Annual Sales: $9.3M
Cash Flow: $-182.3M
Price / Cash Flow: 0
Annual Sales: $-6.51
Price / Book: 0

Profitability

EPS (TTM): -2.41000
Net Income (TTM): $-438.86M
Gross Margin: $6.86M
Return on Equity: 0%
Return on Assets: -62.51%

BridgeBio Pharma Earnings Forecast

Key BridgeBio Pharma Financial Ratios

  • The Gross Profit Margin over the past 7 years for BBIO is 73.71%.
  • The Selling, General & Administrative Expenses for BBIO have been equal to 1,618.73% of Gross Profit Margin.
  • The Research & Development expenses have been 4,898.54% of Revenue.
  • The Interest Expense is -12.64% of Operating Income.
  • The Net Earning history of BBIO is -6,913.92% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 1 years.

BridgeBio Pharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BBIO
CUSIP: 10806X
Website: bridgebio.com

Debt

Debt-to-Equity Ratio: -1.4
Current Ratio: 3.19
Quick Ratio: 1.92

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BBIO Technical Analysis vs Fundamental Analysis

Buy
57
BridgeBio Pharma (BBIO) is a Buy

Is BridgeBio Pharma a Buy or a Sell?

  • BridgeBio Pharma stock is rated a Buy
    The current BridgeBio Pharma [BBIO] share price is $23.42. The Score for BBIO is 57, which is 14% above its historic median score of 50, and infers lower risk than normal.